Skip to main content
Equibles
DSGN logo

DSGN · Design Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track DSGN — free

Use DSGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DSGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.55 +0.34 (+3.33%) Play latest call Q3 2025 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$653.81M
Shares
64.04M
Volume · Nov 9 66.23K Avg daily vol (3M) 581.33K

Design Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Design Therapeutics, Inc. (DSGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)

Embed Design Therapeutics, Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview
                
            

        

        
    

    




    


    
    

        

            
            
            
            
        

            

                
                    
                    
                    
                    
                    
            

        
        
    


    
    

            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-06-04

                


                
                

                    
Design Therapeutics, Inc. (DSGN) June 4, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-05-18

                


                
                

                    
Design Therapeutics, Inc. (DSGN) May 18, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q1

                    
2026-04-28

                


                
                

                    
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0

                                

                                

                                    
Diluted EPS

                                    
$-0.29

                                

                                

                                    Rev · 5q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q3

                    
2025-11-05

                


                
                

                    
Design Therapeutics, Inc. (DSGN) Q3 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Friedreich's Ataxia (FA) clinical data
                                Muscle frataxin expression
                                Study design and disclosure timing
                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.30

                                

                                

                                    Rev · 4q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q1

                    
2025-05-07

                


                
                

                    
Design Therapeutics, Inc. (DSGN) Q1 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                mFARS clinical data and dose response
                                Dose exploration beyond 1 MPK
                                Friedreich's Ataxia clinical proof-of-concept
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$0

                                

                                

                                    
Diluted EPS

                                    
$-0.31

                                

                                

                                    Rev · 4q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q4

                    
2024-03-19

                


                
                

                    
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Friedreich Ataxia Program (DT-216 / DT-216P2)
                                GeneTAC Platform Differentiation
                                Pharmacokinetics and Formulation Improvements
                    

                


                
                

                        Results not yet reported
                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY22 · Q1

                    
2022-05-09

                


                
                

                    
Design Therapeutics, Inc. (DSGN) Q1 2022 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.24

                                

                                

                                    Rev · 3q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY21 · Q3

                    
2021-11-09

                


                
                

                    
Design Therapeutics, Inc. (DSGN) Q3 2021 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Diluted EPS

                                    
$-0.21

                                

                                

                                    Rev · 3q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
    

    

        
Showing 1–8 of 8 webcasts

    

    

    
    


        

    

        

            

                Key facts
                    
                        CIK
                        1807120
                    
                    
                        CUSIP
                        25056L103
                    
                    
                        13F (30d)
                        53 filings
                        41 filers
                    
                    
                    
                         Visit website
                        
                    
                    
                         Investor relations